CLPT ClearPoint Neuro, Inc.

Nasdaq clearpointneuro.com


$ 16.05 $ 0.84 (5.61 %)    

Friday, 07-Nov-2025 19:41:34 EST
QQQ $ 612.14 $ 1.56 (0.26 %)
DIA $ 470.45 $ 1.64 (0.35 %)
SPY $ 672.31 $ 2.95 (0.44 %)
TLT $ 89.45 $ -0.19 (-0.21 %)
GLD $ 367.77 $ 0.35 (0.1 %)
$ 15.81
$ 14.97
$ 16.00 x 60
$ 17.00 x 400
$ 14.71 - $ 16.24
$ 9.76 - $ 30.10
2,049,439
na
449.37M
$ 1.62
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-12-2025 06-30-2025 10-Q
3 05-13-2025 03-31-2025 10-Q
4 02-26-2025 12-31-2024 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-07-2024 06-30-2024 10-Q
7 05-07-2024 03-31-2024 10-Q
8 03-12-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 05-11-2023 03-31-2023 10-Q
12 03-01-2023 12-31-2022 10-K
13 11-08-2022 09-30-2022 10-Q
14 08-09-2022 06-30-2022 10-Q
15 05-11-2022 03-31-2022 10-Q
16 03-08-2022 12-31-2021 10-K
17 11-09-2021 09-30-2021 10-Q
18 08-12-2021 06-30-2021 10-Q
19 05-11-2021 03-31-2021 10-Q
20 03-22-2021 12-31-2020 10-K
21 11-12-2020 09-30-2020 10-Q
22 08-13-2020 06-30-2020 10-Q
23 05-13-2020 03-31-2020 10-Q
24 03-27-2020 12-31-2019 10-K
25 11-13-2019 09-30-2019 10-Q
26 08-12-2019 06-30-2019 10-Q
27 05-13-2019 03-31-2019 10-Q
28 04-01-2019 12-31-2018 10-K
29 11-13-2018 09-30-2018 10-Q
30 08-14-2018 06-30-2018 10-Q
31 05-15-2018 03-31-2018 10-Q
32 03-21-2018 12-31-2017 10-K
33 11-06-2017 09-30-2017 10-Q
34 08-11-2017 06-30-2017 10-Q
35 05-09-2017 03-31-2017 10-Q
36 03-09-2017 12-31-2016 10-K
37 11-09-2016 09-30-2016 10-Q
38 08-15-2016 06-30-2016 10-Q
39 05-06-2016 03-31-2016 10-Q
40 03-25-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 clearpoint-neuro-narrows-fy2025-sales-guidance-from-36000m-41000m-to-36000m-38000m-vs-37650m-est

ClearPoint Neuro (NASDAQ:CLPT) narrows FY2025 sales outlook from $36.000 million-$41.000 million to $36.000 million-$38.000 mil...

 clearpoint-neuro-q3-eps-021-misses-020-estimate-sales-8861m-miss-9600m-estimate

ClearPoint Neuro (NASDAQ:CLPT) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(...

 clearpoint-neuro-to-acquire-irras-holdings-for-5m-in-cash-13m-in-common-shares

ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering...

 clearpoint-neuro-shares-are-trading-higher-wednesday-whats-going-on

ClearPoint Neuro Inc. (NASDAQ:CLPT) shares are trading higher Wednesday after the company announced results from a Phase I-II c...

 clearpoint-neuro-reports-phase-i-ii-results-for-prism-laser-system-in-glioblastoma-study-improved-survival-compared-to-matched-open-surgery-controls-safe-feasible-and-reproducible-workflow-median-ablation-time-65-minutes

ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering...

 clearpoint-neuro-secures-regulatory-approvals-in-canada-hong-kong-and-taiwan-expanding-clinical-access-to-34-countries

The clearly established history across global regulatory bodies is expected to de-risk BioPharma partners' pathways towards...

 clearpoint-neuro-unveils-robotic-neuro-navigation-system-to-advance-cell-and-gene-therapy-procedures

New Product Category Will Enable Added Flexibility to Support Commercial Launches of Cell and Gene TherapySOLANA BEACH, CALIFOR...

 why-pepgen-shares-are-trading-higher-by-112-here-are-20-stocks-moving-premarket

Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced the launch of an underwritt...

 clearpoint-neuro-secures-fda-clearance-for-15t-mri-use-expanding-reach-for-prism-neuro-laser-system

ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering...

 clearpoint-neuro-affirms-fy2025-sales-guidance-of-36000m-41000m-vs-38150m-est

ClearPoint Neuro (NASDAQ:CLPT) affirms FY2025 sales outlook from $36.000 million-$41.000 million to $36.000 million-$41.000 mil...

 clearpoint-neuro-q2-eps-021-misses-018-estimate-sales-9215m-beat-9200m-estimate

ClearPoint Neuro (NASDAQ:CLPT) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(...

 clearpoint-neuro-achieves-key-milestones-with-first-us-commercial-gene-therapy-infusions-using-smartflow-device-for-aadc-deficiency

ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering pre...

 stifel-maintains-buy-on-clearpoint-neuro-raises-price-target-to-9

Stifel analyst Mathew Blackman maintains ClearPoint Neuro (NASDAQ:CLPT) with a Buy and raises the price target from $8 to $9.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION